(BTCY) Is A Nasdaq Former Champ Rocking 5 Potential Catalysts Including Recent FDA Clearance News

Holy guacamole. Did you see what happened with JFIL? (BTCY) Is A Nasdaq Former Champ Rocking 5 Potential Catalysts Including Recent FDA Clearance News [Zacks Small-Cap Research Tags BTCY With $7.50 Price Target]( February 23rd Dear Reader, Holy guacamole. Did you see what happened with JFIL? Released at 9:30AM EST Tuesday morning, past champ JFIL decided to put on the champion's crown once again. Opening at $.0445, this breakout runner blasted its way up the charts to a high of $.12 on the session. Overall, that run resulted in an intraday surge of approximately 169%. Not too bad of a way to start the short week, eh? But that was then. This is now. It's time to turn your attention to a Nasdaq past champ that's champing at the bit to get back on your radar. This has been a previous $1.00+ short term runner on multiple occasions after my alerts. Now it could be lined up once again for another possible breakout due to 5 potential breakout catalysts. So, for the morning of February 23rd, there is only one profile to have on your radar: *Biotricity, Inc. (BTCY)* Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. And right now BTCY has 5 potential catalysts that could spark it to a potential vertical surge near term. Here's what you need to know: No. 1 - $7.50 Price Target From Zacks Small-Cap Research No. 2 - YOY Revenue Gains Announced No. 3 - Biotres Device Receives FDA Clearance No. 4 - Distribution On Amazon Could Be True Game-Changer No. 5 - Bioheart Heart Monitor Product Now Available But more on them in a second... Its Foundational Product, Bioflux, is Targeting a Growing and Underserved Market The company’s first and primary solution, Bioflux, addresses the growing and underserved Mobile Cardiac Telemetry (MCT) market. Bioflux is a high-precision, single-unit MCT device providing real-time monitoring and transmission of ECG information from ambulatory patients. This entire system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows to better detect, diagnose, and monitor. For medical practitioners, this solution looks to be technologically superior and more financially attractive too. Clinicians designed the Bioflux online portal for clinicians. After all, the prime features of the product were built after speaking with numerous healthcare professionals and seeing what their most requested features were. And right now, BTCY has 5 potential catalysts that could spark a possible breakout. Here's what you need to know... No. 1 Potential BTCY Breakout Catalyst - $7.50 Price Target From Zacks Small-Cap Research This month, Zacks Small-Cap Research initiated coverage on BTCY and slapped it with a [$7.50 price target.]( From Tuesday's closing valuation, that provides BTCY with triple-digit upside potential upside from its current trading levels. Here are the key highlights from the report: - We had initiated coverage of Biotricity Inc. (BTCY) last week with a valuation price target of $7.50 per share... - 93% sales growth in the December quarter was nice to see despite Omicron drag. - Triple-digit sales growth this March 2022 fiscal year and next year was guided. - 33%+ salesforce growth in the past three to four months and a goal to double it during calendar 2022. - Biotres could be a good growth contributor by the end of the calendar year after receiving FDA clearance received last month. - Monthly care subscription (Cardiac & Chronic) offering should be available by July 1st . We deem this a big revenue contributor for the March 2024 fiscal year (see our model). Current sales reps will cross-sell and upsell the new offering while visiting clinics and offices for continued penetration of Bioflux. Part of building out a complete suite solution and ecosystem. - Greenshoots being seen the past few weeks of initial fading of the Omicron overhang variant of CV-19 created from late November through mid-January. Some patients opted to not go see their cardiologist and instead delay until Omi-cron would fade. Some offices were closed during the initial spike in Omi-cron and over the holidays. We expect there to be some catch-up demand on this front for March and April as CVD cases have subsided recently. - Chips shortages are not much of a supply constraint and the company believes they are insulated. - International expansion opportunity could be pursued with distribution partners and for countries that recognize US FDA approval instead of having to start from scratch for slower regulatory burden. - $14Mn Cash at late December will support funding of working capital growth for devices, hiring additional salesforce and monthly care subscription rollout. [Read the full report here.]( ----- No. 2 Potential BTCY Breakout Catalyst - YOY Revenue Gains Announced Biotricity Releases Fiscal 2022 Third Quarter Fin-an-cial Results - 93% YOY Revenue Gains to $1.93Mn - Revenue Outpaces SG&A Increase by 2.2x - Cash Position of $16.8Mn at Quarter End Is Highest Ever - Continues to Anticipate Full-Year Triple-Digit Revenue Growth REDWOOD CITY, CA / ACCESSWIRE / February 14, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year's third quarter ended December 31, 2021. Q3-FY22 fin-an-cial and operating highlights include: - Revenue of $1.93Mn, an increase of 93% year-over-year and sequentially 7% above the $1.8- Mn reported in Q2FY22. - Scaling well - SG&A rose just 40%, R&D up 32%, compared with 93% revenue increase. - Net loss of $7.34Mn or $0.15 per share, impacted by one-time derivative fair value and accretion expenses of $1.34Mn during the quarter; excluding these non-recurring items would result in an adjusted net loss of $6.0Mn or $0.12 per share. "The December quarter was pivotal for our company," said Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity. "We were still able to generate modest sequential growth despite the challenges of omi-cron, clinical closures, and reduced scheduling and staffing." "We also had several game-changing product introductions, as well as the foundational FDA clearance of Biotres, which has greatly expanded our total addressable cardiac market and has positioned us well to make 2022 an inflectional year. Our recently completed $1Mn de-bt fin-an-cing has firmly positioned us to aggressively pursue our expansion plans and solidify our sector tech leadership." [...] [Read the full article here.]( ----- No. 3 Potential BTCY Breakout Catalyst - Biotres Device Receives FDA Clearance Biotricity Receives FDA 510(k) Clearance for its Biotres Cardiac Monitoring Device Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2Bn-dollar holter market REDWOOD CITY, CA / ACCESSWIRE / January 24, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today reported it has received 510(k) clearance from the U.S. Food and Dr-ug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients. Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO commented, "We are extremely proud of this accomplishment and its potential to reshape the future of cardiac prevention and monitoring with this novel platform. With Biotres receiving 510(k) clearance, we now have another option for providing a secondary product for doctors and hospitals to meet their patients' cardiac monitoring needs. Coupled with the recent successful non-dilutive fin-an-cing, we believe we are well capitalized to execute the expansion of our commercialization efforts." [...] [Read the full article here.]( ----- No. 4 Potential BTCY Breakout Catalyst - Distribution On Amazon Could Be True Game-Changer Biotricity Expands Distribution of New Bioheart Device on Amazon New Heart Monitoring Solution Delivers Personalized Heart Health Insights Directly to Your Smartphone REDWOOD CITY, CA / ACCESSWIRE / December 28, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced it has expanded the distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring technology used by physicians, on Amazon(dot)com. Last month the company launched commercial sales of its Bioheart device. To improve availability and expand outreach, Biotricity has now listed it for purchase on Amazon(dot)com at: Bioheart on Amazon for $199 with a special introductory price of $149 for a limited time. You can view the Bioheart heart monitor in use here. "We are aiming to transform the cardiac health marketplace and believe the Bioheart system will play an important role in that endeavor," said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, "The Bioheart device is an important component of our full spectrum, ‘virtual cardiac clinic' of mobile cardiac care and lifestyle solutions. It will be fully integrated with a growing number of cardiology practices through our cloud-based ‘Biosphere' ecosystem that we plan to fully roll out in 2022, allowing physicians to get a more holistic view of a patient's health." "The ability to offer Bioheart on Amazon expands the availability for the public to easily access the benefits of this exciting technology," Dr. Waqaas added. The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company's total addressable market by $1.24B. Heart conditions are intermittent, requiring long-term data collection for effective insights and lifestyle management. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots and long-term data collection. Introducing a groundbreaking new capability, users can collect data for hours, days, weeks, months, and even years! They can create snapshots of rhythm data by reviewing past data and marking it for personal records. These are first-of-its-kind features that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health. [Read the full article here.]( ----- No. 5 Potential BTCY Breakout Catalyst - Bioheart Heart Monitor Product Now Available Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone REDWOOD CITY, Calif., November 10, 2021--(BUSINESS WIRE)--Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. Showcased in prototype form at CES 2020, Bioheart has shipped to preorder customers and is now available for purchase at www(dot)bioheart(dot)com. The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B, the global heart rate monitoring market. "Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey," said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. [...] [Read the full article here.]( ----- BTCY Recap: 5 Potential Breakout Catalysts For This Nasdaq MedTech Profile No. 1 - $7.50 Price Target From Zacks Small-Cap Research   No. 2 - YOY Revenue Gains Announced   No. 3 - Biotres Device Receives FDA Clearance No. 4 - Distribution On Amazon Could Be True Game-Changer   No. 5 - Bioheart Heart Monitor Product Now Available -----   Coverage is officially reinitiated on BTCY. When you have time later, do this: Get BTCY on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer  I am not a lic-ensed fina-ncial adviser. All potential percentage gains are based on from the low to the high of day. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 9/15/21 and ending on 9/16/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 9/15/21 and ending on 9/16/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid sixty-seven thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 10/7/21 and ending on 10/8/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid two thousand five hundred USD via ACH. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor. Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 10/7/21 and ending on 10/8/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid fifteen thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a one day period beginning on 10/29/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid two thousand five hundred USD via ACH. We own zero shares of (BTCY). To date we have been compensated a total of twenty thousand USD via ACH to disseminate information about (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a one day period beginning on 10/29/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid ten thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). To date we have been compensated a total of ninety-two thousand five hundred USD via bank wire transfer to disseminate information about (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 12/27/21 and ending on 12/28/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid five thousand USD via ACH. We own zero shares of (BTCY). To date we have been compensated a total of twenty-five thousand USD via ACH to disseminate information about (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 12/27/21 and ending on 12/28/21 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid twenty-five thousand USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 1/24/22 and ending on 1/25/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (BTCY). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/24/22 and ending on 1/25/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 2/23/22 and ending on 2/24/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (BTCY). To date we have been compensated a total of forty thousand USD via ACH to disseminate information about (BTCY). This fifteen thousand USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed. An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 2/23/22 and ending on 2/24/22 to publicly disseminate information about (BTCY) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (BTCY). To date we have been compensated a total of two hundred thousand USD via bank wire transfer to disseminate information about (BTCY). This eighty-two thousand five hundred USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed. Pursuant to an agreement between FierceInvestor (FI) and StockNewsWire LLC, FI was hired for a period beginning on 1/20/22 and ending on 1/21/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. We were paid fifteen thousand USD via ACH. We own zero shares of (IMMX). An owner of StockNewsWire LLC owns an interest in FierceInvestor (FI). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/20/22 and ending on 1/21/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (IMMX). We have not been compensated for the profile on (JFIL). We do not own any shares of (JFIL). Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net